InsiderTrades

Form 4 for VRTX Vertex Pharmaceuticals

Accepted 2023-02-28 00:00:00 ET · period of report 2023-02-24 · accession 0001209191-23-013708 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
M 2023-02-28 2023-02-27 VRTX Arbuckle Stuart A EVP, COO S - Sale $287.47 -5,034 57.8K -8% -$1.45M
2023-02-28 2023-02-24 VRTX Arbuckle Stuart A EVP, COO F - Tax $289.12 -4,714 61.6K -7% -$1.36M

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-02-27 S D 800 $288.92 56,556 D — — (F5) Open market sales reported on this line occurred at a weighted average price of $288.92 (range $288.57 to $289.38). (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
2 Common Common Stock 2023-02-27 S D 400 $287.59 57,356 D — — (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. (F4) Open market sales reported on this line occurred at a weighted average price of $287.59 (range $287.57 to $287.60).
3 Common Common Stock 2023-02-27 S D 3,834 $287.16 57,756 D — — (F3) Open market sales reported on this line occurred at a weighted average price of $287.16 (range $286.57 to $287.51). (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
4 Common Common Stock 2023-02-24 F D 4,714 $289.12 61,590 D — —